8-K: Beyond Air Reports Solid Revenue Growth and Pipeline Progress in Q3 Fiscal Year 2024

Beyond Air announced a significant 60% sequential revenue increase in Q3 FY2024, alongside advancements in their LungFit product line and cancer treatment programs.

Summary

• Beyond Air reported a 60% sequential revenue increase in the third quarter of fiscal year 2024 compared to the second quarter.
• The company's LungFit PH system saw increased commercial demand, with a 100% increase in filters shipped quarter over quarter.
• A PMA supplement for the LungFit PH label expansion to include cardiac surgery was accepted for filing by the FDA and is under substantive review.
• The company reiterated its fiscal year 2025 revenue guidance of $12 million to $16 million.
• A U.S. pilot trial for LungFit PRO to treat viral community-acquired pneumonia (VCAP) is underway, with top-line data expected mid-year 2025.
• The Phase 1 study evaluating Beyond Cancer's ultra-high concentration nitric oxide (UNO) in solid tumors cleared the first cohort with no reported dose-limiting toxicities.
• The company's net loss for the quarter was $16.2 million, or a loss of $0.50 per share, compared to a net loss of $12.7 million, or a loss of $0.43 per share, in the same quarter of the previous year.
• Total cash burn for the quarter was $12.7 million, partially offset by a $5.5 million raise on its ATM.
• As of December 31, 2023, the company had $31.4 million in cash, cash equivalents, and marketable securities, plus $5.2 million held on deposit by its contract manufacturer.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and progress in clinical trials, but the significant net loss and cash burn temper the overall sentiment. The company is making progress but still has a long way to go.

Positives

• The company achieved significant sequential revenue growth of 60% in the third quarter of fiscal year 2024.
• Commercial demand for the LungFit PH system is increasing, with a 100% increase in filter shipments quarter over quarter.
• The FDA has accepted the PMA supplement for the LungFit PH label expansion to include cardiac surgery, which could broaden its use.
• The company is on track with its LungFit PRO trial for VCAP, with top-line data expected in mid-2025.
• The Phase 1 study of UNO for solid tumors has shown no dose-limiting toxicities in the first cohort.
• The company has reiterated its revenue guidance for fiscal year 2025, indicating confidence in future sales.

Negatives

• The company experienced a net loss of $16.2 million for the quarter, which is higher than the $12.7 million loss in the same quarter of the previous year.
• Research and development expenses increased by $1.8 million compared to the same quarter last year.
• General and administrative expenses increased by $0.9 million compared to the same quarter last year.
• The company had a total cash burn of $12.7 million for the quarter.

Risks

• The company is experiencing significant cash burn, with $12.7 million spent in the quarter.
• The company is dependent on regulatory approvals for its products, and delays could impact revenue.
• The company is facing increased research and development costs, which could impact profitability.
• The company is subject to competition from other companies in the medical device and biopharmaceutical industries.
• The company's success is dependent on the successful completion of clinical trials and the commercialization of its products.

Future Outlook

The company anticipates continued growth in demand for its LungFit PH system and expects to meet accelerating demand over the next several quarters. They also expect to initiate a pivotal trial for LungFit PRO in the 2025/2026 pneumonia season and a U.S. trial for LungFit GO in 2025. The company plans to initiate a first-in-human study for the treatment of ASD in 2025.

Management Comments

• Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, stated that the positive commercial traction gives them even more confidence in hitting their fiscal year 2025 sales guidance of $12 to $16 million.

Industry Context

The company operates in the medical device and biopharmaceutical industries, focusing on nitric oxide therapies. The increasing demand for their LungFit PH system and the progress in clinical trials for other LungFit systems and cancer treatments align with the growing need for innovative respiratory and oncology solutions. The company's focus on nitric oxide aligns with the growing interest in its therapeutic potential.

Comparison to Industry Standards

• The 60% sequential revenue growth is a positive sign, but the company's overall revenue of $0.4 million is still relatively low compared to established medical device companies.
• The net loss of $16.2 million is significant and highlights the company's current stage of development, which is typical for companies investing heavily in R&D and clinical trials.
• The cash burn of $12.7 million is also substantial, indicating the need for continued funding. Companies like Inogen (INGN) and ResMed (RMD) in the respiratory space have much higher revenues and are profitable, but they are also more mature.
• The progress in clinical trials for LungFit PRO and the UNO cancer program is promising, but the timelines for pivotal trials and potential FDA approvals are still uncertain. Companies like Gilead (GILD) and Bristol Myers Squibb (BMY) have established oncology pipelines and are benchmarks for clinical trial success.
• The company's focus on nitric oxide is unique, but it also carries risks as it is a relatively new area of therapeutic development. Companies like Mallinckrodt (MNK) have experience with inhaled nitric oxide, but their focus is on different applications.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and clinical trial progress, but concerned about the net loss and cash burn.
• Employees may be affected by the management changes, but the company's growth could provide opportunities.
• Customers may benefit from the expanded use of LungFit PH and the development of new treatments.
• Suppliers may see increased demand for their products as the company grows.
• Creditors may be concerned about the company's cash burn and net loss.

Next Steps

• The company will continue to ramp up manufacturing of upgraded LungFit PH devices to meet growing demand.
• The company will continue the substantive review of the PMA supplement for LungFit PH with the FDA.
• The company will continue the U.S. pilot trial of LungFit PRO for VCAP.
• The company will enroll the 50,000 ppm cohort of the Phase 1 Study for UNO.
• The company will prepare to enter the Phase Ib portion of the UNO study.
• The company plans to initiate a U.S. trial for LungFit GO for NTM in calendar year 2025, pending discussion with the FDA.
• The company plans to initiate a first-in-human study for the treatment of ASD in 2025.
• The company will conduct an executive search for a new Chief Commercial Officer.

Key Dates

Keywords

Nitric Oxide, LungFit PH, LungFit PRO, LungFit GO, Beyond Cancer, UNO, Pneumonia, VCAP, NTM, Autism, Medical Device, Biopharmaceutical, FDA, Clinical Trials, Revenue